

Feedback PLC

09:59 24 Oct 2019

Feedback sees revenues surge 23% in latest full year

Feedback PLC (LON:FDBK) has reported a 23% rise in full-year revenues as its product lines continue to grow.

For the 12 months ended 31 May, the medical imaging specialist saw its revenue increase to £563,092 from £458,389, with 40% of turnover attributable to one customer.

WATCH: Feedback PLC 'very close to standing up some pilots' for its Bleepa app

The group's pre-tax loss widened slightly to £1.13m from £750,000 due to changes in accounting practices and increased investments in staff as it gears up to deliver new products.

Looking ahead, Feedback said its new product, Bleepa, an encrypted and secure way for doctors to send images of X-ray and other scans to each other to aid diagnosis and treatment, had generated "considerable interest" following its launch in September and that it was already arranging demos for several potential customers.

Tom Oakley, Feedback's chief executive pointed out that, following fundraisings of around £3.38m over the year, the company is "well positioned" to build its capabilities and support the roll-out of Bleepa both in the UK and overseas.

"This has been a transformational year for Feedback and we believe that we have the technology and strategy to make a meaningful change in the medical imaging and communications market", he said in a statement.

In mid-morning trading on Thursday, Feedback's shares were 2% lower at 1.3p.

Price: 0.975

Market Cap: £5.26 m

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: FDBK

Listing: LSE

52 week High Low
2.1558 0.6301

Sector: Hardware & electrical equipment

Website: www.fbk.com

Company Synopsis:

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through our trading subsidiary, Feedback Medical Limited. Their products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, such as cancer.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).